公开(公告)号：US12128051B2

公开(公告)日：2024-10-29

申请号：US17961765

申请日：2022-10-07

Applicant: WisTa Laboratories Ltd.

Inventor： Claude Michel Wischik ,  Bjorn Olaf Schelter ,  Damon Jude Wischik ,  John Mervyn David Storey

IPC: A61K31/5415 ,  A23L33/105 ,  A23L33/12 ,  A23L33/15 ,  A23P10/28 ,  A23P10/30 ,  A61K45/06 ,  A61P25/28 ,  B65D75/36

CPC classification number: A61K31/5415 ,  A23L33/105 ,  A23L33/12 ,  A23L33/15 ,  A23P10/28 ,  A23P10/30 ,  A61K45/06 ,  A61P25/28 ,  B65D75/36 ,  A23V2002/00 ,  B65D2203/02

Abstract: The invention provides novel regimens for treatment of neurodegenerative disorders utilising methylthioninium (MT)-containing compounds. The regimens are based on novel findings in relation to the dosage of MT compounds, and their interaction with symptomatic treatments based on modulation of acetylcholinesterase levels.

公开(公告)号：US20240343704A1

公开(公告)日：2024-10-17

申请号：US18288213

申请日：2022-05-02

Applicant: Ontario Institute for Cancer Research (OICR)

Inventor： Anh Chau ,  Methvin Isaac ,  Babu Joseph ,  Radek Laufer ,  Gennady Poda ,  Michael Prakesch ,  Pandiaraju Subramanian ,  David Uehling ,  Iain Watson ,  Brian Wilson ,  Tao Xin

IPC: C07D401/04 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/4995 ,  A61K31/517 ,  A61K31/519 ,  A61K31/53 ,  A61K31/5377 ,  A61K31/538 ,  A61K31/5383 ,  A61K31/5386 ,  A61K31/541 ,  A61K31/5415 ,  A61K31/55 ,  A61K31/551 ,  A61K31/553 ,  A61K31/695 ,  C07D401/14 ,  C07D405/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D471/04 ,  C07D471/10 ,  C07D487/04 ,  C07D487/10 ,  C07D491/048 ,  C07D491/107 ,  C07D491/113 ,  C07D495/04 ,  C07D498/04 ,  C07D498/10 ,  C07F7/08

CPC classification number: C07D401/04 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/4995 ,  A61K31/517 ,  A61K31/519 ,  A61K31/53 ,  A61K31/5377 ,  A61K31/538 ,  A61K31/5383 ,  A61K31/5386 ,  A61K31/541 ,  A61K31/5415 ,  A61K31/55 ,  A61K31/551 ,  A61K31/553 ,  A61K31/695 ,  C07D401/14 ,  C07D405/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D471/04 ,  C07D471/10 ,  C07D487/04 ,  C07D487/10 ,  C07D491/048 ,  C07D491/107 ,  C07D491/113 ,  C07D495/04 ,  C07D498/04 ,  C07D498/10 ,  C07F7/0836

Abstract: The present application relates to halo-substituted heterocyclic compounds of Formula (I): or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting HPK1, such as cancer.

公开(公告)号：US20240342173A1

公开(公告)日：2024-10-17

申请号：US18439926

申请日：2024-02-13

Applicant: THE CHILDREN'S MEDICAL CENTER CORPORATION ,  DANA-FARBER CANCER INSTITUTE, INC.

Inventor： James BRADNER ,  Jun QI ,  Dennis BUCKLEY ,  Leonard I. ZON ,  Elizabeth MACARI

IPC: A61K31/517 ,  A61K31/225 ,  A61K31/403 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5415 ,  A61K31/55 ,  A61K31/7048 ,  A61K45/06 ,  A61P7/06

CPC classification number: A61K31/517 ,  A61K31/225 ,  A61K31/403 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5415 ,  A61K31/55 ,  A61K31/7048 ,  A61P7/06 ,  A61K45/06

Abstract: The present invention relates to methods, compositions and kits for treatment of ribosomal disorders and ribosomopathies, e.g. Diamond Blackfan anemia (DBA). In some embodiments, the invention relates to the use of novel classes of compounds, i.e. inhibitors of RSK (p90S6K); inhibitors of p70S6K; and inhibitors of rps6, to treat ribosomal disorders and ribosomopathies. In some embodiments, the invention relates to the use of specific Chk2 inhibitors and to the use of specific phenothiazine derivatives to treat ribosomal disorders and ribosomopathies, e.g. DBA.

公开(公告)号：US20240327393A1

公开(公告)日：2024-10-03

申请号：US18574309

申请日：2022-07-08

Applicant: SIRONAX LTD.

Inventor： Jianguang HAN ,  Zhiyuan ZHANG ,  Weijie HOU ,  Yimin JIANG ,  Yanping XU

IPC: C07D413/12 ,  A61K31/366 ,  A61K31/4035 ,  A61K31/416 ,  A61K31/4184 ,  A61K31/423 ,  A61K31/428 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/472 ,  A61K31/496 ,  A61K31/498 ,  A61K31/506 ,  A61K31/517 ,  A61K31/5355 ,  A61K31/536 ,  A61K31/538 ,  A61K31/5383 ,  A61K31/5415 ,  A61K31/5513 ,  A61K31/553 ,  C07D209/46 ,  C07D217/04 ,  C07D217/06 ,  C07D263/58 ,  C07D277/82 ,  C07D279/16 ,  C07D311/18 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/14 ,  C07D471/04 ,  C07D487/04 ,  C07D491/08 ,  C07D498/04 ,  C07D498/08

CPC classification number: C07D413/12 ,  A61K31/366 ,  A61K31/4035 ,  A61K31/416 ,  A61K31/4184 ,  A61K31/423 ,  A61K31/428 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/472 ,  A61K31/496 ,  A61K31/498 ,  A61K31/506 ,  A61K31/517 ,  A61K31/5355 ,  A61K31/536 ,  A61K31/538 ,  A61K31/5383 ,  A61K31/5415 ,  A61K31/5513 ,  A61K31/553 ,  C07D209/46 ,  C07D217/04 ,  C07D217/06 ,  C07D263/58 ,  C07D277/82 ,  C07D279/16 ,  C07D311/18 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/14 ,  C07D471/04 ,  C07D487/04 ,  C07D491/08 ,  C07D498/04 ,  C07D498/08

Abstract: Provided are compounds of Formula I, compositions comprising the same, and methods of using the same, including use in treating various diseases and conditions, e.g., those involving ferroptosis.

公开(公告)号：US20240293427A1

公开(公告)日：2024-09-05

申请号：US18654262

申请日：2024-05-03

Applicant: G2GBIO, INC.

Inventor： Geonho KIM ,  Jinwoo LEE ,  Hyejung JUNG ,  Jaemook CHOI ,  Jeongsu BYUN ,  Juhan LEE ,  Eunyoung SEOL ,  Heeyong LEE

IPC: A61K31/573 ,  A61K9/00 ,  A61K9/16 ,  A61K31/27 ,  A61K31/407 ,  A61K31/445 ,  A61K31/522 ,  A61K31/5415 ,  A61K31/56 ,  A61K38/08 ,  A61K38/09 ,  A61K38/26 ,  A61P29/00

CPC classification number: A61K31/573 ,  A61K9/0019 ,  A61K9/1647 ,  A61K31/27 ,  A61K31/407 ,  A61K31/445 ,  A61K31/522 ,  A61K31/5415 ,  A61K31/56 ,  A61K38/08 ,  A61K38/09 ,  A61K38/26 ,  A61P29/00

Abstract: The present invention is a pharmaceutical kit for combined parenteral administration, comprising a first formulation containing a first drug, and a second formulation containing a second drug and a parenteral drug delivery system, and it can be used for preventing, reducing or treating an inflammatory reaction of a subject caused by the parenteral drug delivery system of the second formulation, controlling decomposition of the parenteral drug delivery system contained in the second formulation, or increasing bioavailability of the second drug contained in the second formulation.

公开(公告)号：US12042471B2

公开(公告)日：2024-07-23

申请号：US15794886

申请日：2017-10-26

Applicant: PhotoPharmics, Inc.

Inventor： Gregory Lynn Willis

IPC: A61K31/13 ,  A61K9/00 ,  A61K9/48 ,  A61K9/51 ,  A61K31/165 ,  A61K31/4515 ,  A61K31/454 ,  A61K31/5415 ,  A61P25/16

CPC classification number: A61K31/13 ,  A61K9/0048 ,  A61K31/165 ,  A61K31/4515 ,  A61K31/454 ,  A61K31/5415 ,  A61K9/0051

Abstract: A method for the treatment and/or prophylaxis of a neurological and/or neuropsychiatric disorder associated with altered dopamine function comprising administering to the eye of a patient in need thereof an effective amount of an agent that modulates neurotransmitter production or function.

公开(公告)号：US20240226303A9

公开(公告)日：2024-07-11

申请号：US18548645

申请日：2022-03-04

Applicant: RECKITT BENCKISER HEALTH LIMITED

Inventor： Ammar ALMAJAAN ,  Gavin Paul ANDREWS ,  David Simon JONES ,  Mariana Palmeira BEZERRA ,  Walkiria Santos SCHLINDWEIN ,  Karina WOJDAT

IPC: A61K47/32 ,  A61K31/167 ,  A61K31/192 ,  A61K31/196 ,  A61K31/405 ,  A61K31/5415 ,  A61K31/616

CPC classification number: A61K47/32 ,  A61K31/167 ,  A61K31/192 ,  A61K31/196 ,  A61K31/405 ,  A61K31/5415 ,  A61K31/616

Abstract: A solidified melt extrudate comprising an active pharmaceutical ingredient in an amorphous form and a combination of at least two polymers.

公开(公告)号：US20240216268A1

公开(公告)日：2024-07-04

申请号：US18608613

申请日：2024-03-18

Applicant: ALBERTA VETERINARY LABORATORIES LTD

Inventor： Merle Olson

IPC: A61K9/00 ,  A61K9/06 ,  A61K31/167 ,  A61K31/5415 ,  A61P23/02

CPC classification number: A61K9/0017 ,  A61K9/06 ,  A61K31/167 ,  A61K31/5415 ,  A61P23/02

Abstract: The present invention is a topical composition for the treatment of animals, particularly animals in pain, wherein the composition comprises an effective amount of a local anesthetic (e.g., lidocaine) and an analgesic (e.g., meloxicam).

公开(公告)号：US20240180895A1

公开(公告)日：2024-06-06

申请号：US18282173

申请日：2022-03-21

Applicant: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College

Inventor： Jacob Meariman ,  Daniel R. Kapusta ,  Juan Gao

IPC: A61K31/485 ,  A61K31/4965 ,  A61K31/5415 ,  A61K31/635 ,  A61K38/07 ,  A61P9/12 ,  A61P13/12

CPC classification number: A61K31/485 ,  A61K31/4965 ,  A61K31/5415 ,  A61K31/635 ,  A61K38/07 ,  A61P9/12 ,  A61P13/12

Abstract: A method of method of preventing or reversing diuretic resistance, the method comprising administering to the subject an amount of a kappa opioid receptor agonist (KOA) sufficient to selectively increase urine output, wherein the KOA decreases or does not change urinary excretion of electrolytes.

公开(公告)号：US11992560B2

公开(公告)日：2024-05-28

申请号：US17251601

申请日：2018-06-14

Applicant: ALMA MATER STUDIORUM—UNIVERSITÀ DI BOLOGNA

Inventor： Laura Calza ,  Luciana Giardino ,  Maria Letizia Focarete ,  Chiara Gualandi ,  Maria-Laura Bolognesi ,  Nadia Passerini ,  Giampiero Pagliuca ,  Teresa Gazzotti ,  Elisa Zironi

IPC: A61K9/70 ,  A61K9/00 ,  A61K31/12 ,  A61K31/19 ,  A61K31/192 ,  A61K31/196 ,  A61K31/197 ,  A61K31/198 ,  A61K31/40 ,  A61K31/405 ,  A61K31/407 ,  A61K31/42 ,  A61K31/421 ,  A61K31/4418 ,  A61K31/5415 ,  A61K31/5575 ,  A61K31/603 ,  A61K31/704 ,  A61P25/28

CPC classification number: A61K9/70 ,  A61K9/0024 ,  A61K31/12 ,  A61K31/19 ,  A61K31/192 ,  A61K31/196 ,  A61K31/197 ,  A61K31/198 ,  A61K31/40 ,  A61K31/405 ,  A61K31/407 ,  A61K31/42 ,  A61K31/421 ,  A61K31/4418 ,  A61K31/5415 ,  A61K31/5575 ,  A61K31/603 ,  A61K31/704 ,  A61P25/28

Abstract: The present invention relates to electro spun fibers for a local release in the central nervous system of an anti-inflammatory and a promyelinating agent over a defined time-window, in order to limit secondary neurodegeneration triggered by the glutamate release and supported by on-going inflammation. The combined treatment aimed to reduce inflammation and improve remyelination in the very early stage of the pathology improving the chronic clinical outcome of the lesion. In particular the present invention relates to electrospun polymeric fibers, wherein said fibers are loaded with 3,3,5-Triiodo-L-thyronine (T3) and Ibuprofen.